ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

09 May 2023 09:10:46 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

28 Mar 2023 09:39:51 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

23 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

23 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

22 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

09 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

10 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

08 Nov 2022 16:02:00 By Nasdaq GlobeNewswire